<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02756104</url>
  </required_header>
  <id_info>
    <org_study_id>9632</org_study_id>
    <nct_id>NCT02756104</nct_id>
  </id_info>
  <brief_title>T Cell Phenotypes in Amyotropic Lateral Sclerosis (ALS), Influence of Vitamin D</brief_title>
  <acronym>VITALS</acronym>
  <official_title>T Cell Phenotypes in ALS, Influence of Vitamin D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARSLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALS is a devastative disorder characterized by motor neuron degeneration. Median survival is&#xD;
      3 years after onset, but may vary from a few months to more than 30 years. Various factors&#xD;
      have been suspected to play a role in such a variation, but recently, it has been described&#xD;
      that regulatory T-lymphocytes (T regs) may mediate ALS progression and survival. Vitamin D is&#xD;
      an hormone know to regulated T reg function in vivo and in vitro. It have recently&#xD;
      demonstrated that vitamin D (VD) levels correlated with ALS prognosis. The investigator want&#xD;
      to go further in the study of the immune processes that could modulate prognosis in ALS. This&#xD;
      could allow proposing VD as a potential treatment of ALS in a future trial. More largely,&#xD;
      this could reinforce arguments in favor of an immune intervention to attenuate the severity&#xD;
      of this devastating disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ALS is a devastative disorder characterized by motor neuron degeneration. Median survival is&#xD;
      3 years after onset, but may vary from a few months to more than 30 years. Various factors&#xD;
      have been suspected to play a role in such a variation, but recently, it has been described&#xD;
      that regulatory T-lymphocytes (T regs) may mediate ALS progression and survival. Vitamin D is&#xD;
      an hormone know to regulated T reg function in vivo and in vitro. It have recently&#xD;
      demonstrated that vitamin D (VD) levels correlated with ALS prognosis and patients with a&#xD;
      severe VD deficiency had a 6 time more rapid evolution than those with normal VD levels. The&#xD;
      investigator want to go further in the study of the immune processes that could modulate&#xD;
      prognosis in ALS. We propose 1- to study T cell phenotypes (Treg, CD4 (cluster of&#xD;
      differentiation 4) -Th1, -Th17, -Th2, CD8 (cluster of differentiation 8)and NK) in ALS vs&#xD;
      controls ; 2- In VD-deficient patients, to analyze the influence of a vitamin D&#xD;
      supplementation on T cell phenotypes ; 3- to study the relationships between T cell&#xD;
      phenotypes and ALS prognostic factors. The project will include 70 ALS patients and 27&#xD;
      controls in this prospective study. VD-deficient patients will be supplemented, according to&#xD;
      national recommendations for 6 months, and the evolution of T cell phenotypes will be&#xD;
      followed over 1 year. We hope to demonstrate first that T cell phenotypes in ALS are&#xD;
      consistent with a pro inflammatory profile, compared to controls, secondly that VD treatment&#xD;
      modulates T cell phenotypes towards a non-inflammatory one and, thirdly, that inflammatory T&#xD;
      cell phenotypes correlate with a worse prognosis of the disease. This could allow proposing&#xD;
      VD as a potential treatment of ALS in a future trial. More largely, this could reinforce&#xD;
      arguments in favor of an immune intervention to attenuate the severity of this devastating&#xD;
      disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2016</start_date>
  <completion_date type="Actual">May 25, 2020</completion_date>
  <primary_completion_date type="Actual">September 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study of T-cell phenotypes in ALS patients and controls</measure>
    <time_frame>6 months</time_frame>
    <description>Analyses of the expression of T cells phenotypes between volunteers and patients with ALS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of vitamin D treatment on T cell phenotypes</measure>
    <time_frame>6 months</time_frame>
    <description>Study the relation between vitamin D blood level and the lymphocytes phenotypes between patient with initial ALS and volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships between expression of T cell phenotypes and ALS criteria</measure>
    <time_frame>6 months</time_frame>
    <description>Study of the relation between the lymphocytes phenotypes expression and prognostic factors of the ALS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships between vitamin D blood level and pronostic factors of the ALS</measure>
    <time_frame>6 months</time_frame>
    <description>Study of the relation between vitamin D blood level and prognostic factors of the ALS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>Volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy People on each collecting blood for phenotyping Tcells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with ALS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with ALS deficient or not in Vitamin D on each collecting blood for phenotyping Tcells.&#xD;
The patients who are deficient in Vitamin D will have supplementation in vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>phenotyping Tcells</intervention_name>
    <description>Collecting blood for analyses of the T cells phenotypes</description>
    <arm_group_label>Patients with ALS</arm_group_label>
    <arm_group_label>Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supplementation in vitamin D</intervention_name>
    <description>Supplementation in vitamin D for the patients who are deficient on vitamin D</description>
    <arm_group_label>Patients with ALS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For the patients :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman with sporadic ALS and a possible, probable or definite diagnosis&#xD;
             regarding the revised Escorial criteria (Forbes et al., 2001). Patients are followed&#xD;
             quarterly according to national recommendations. At the end of the follow up period (1&#xD;
             year for each patient), all patients remaining in the &quot; possible &quot; group of diagnosis&#xD;
             will be excluded.&#xD;
&#xD;
          -  Disease onset (date of onset of muscle weakness) &lt; 18 months at the time of inclusion.&#xD;
&#xD;
          -  Age: 30 to 80 years-old, inclusive.&#xD;
&#xD;
          -  Patient treated by riluzole at a steady dosage since at least 3 months.&#xD;
&#xD;
          -  Patient accepting to give informed consent&#xD;
&#xD;
        Exclusion criteria will be :&#xD;
&#xD;
          -  A previous treatment with VD in the preceding 2 years, whatever the dose used.&#xD;
&#xD;
          -  Patient with an already known autoimmune disorder&#xD;
&#xD;
          -  Patient with severe ALS involvement suggesting that survival over the 1 year follow up&#xD;
             is highly unlikely (ex : tetraplegia, use of non-invasive ventilation for more than 10&#xD;
             hrs/day, ALSFRS-R (ALS Functional Rating Scale) score &lt; à 20).&#xD;
&#xD;
          -  Pregnant or breast-feeding woman.&#xD;
&#xD;
          -  Patient without social security insurance&#xD;
&#xD;
        For the Controls:&#xD;
&#xD;
        Controls will be spouses of our ALS patients. Such a group has the advantage of similar&#xD;
        life style conditions, and frequently similar geographical origin. Controls and ALS&#xD;
        patients will match for age and gender. Controls will also fulfill the following inclusion&#xD;
        and exclusion criteria&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
        •Subject accepting to give informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Subject with an already known neurodegenerative disorder&#xD;
&#xD;
          -  Subject with an already known autoimmune disorder&#xD;
&#xD;
          -  Subject who received a treatment with VD in the preceding 2 years, whatever the dose&#xD;
             used.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Subject without social security insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William CAMU, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigator communicate the global results on demand</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

